Back to top
more

Enanta Pharmaceuticals (ENTA)

(Delayed Data from NSDQ)

$12.37 USD

12.37
67,161

-0.11 (-0.88%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $12.38 +0.01 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sweta Killa headshot

5 Top Performing Stocks of the Best ETF of 1H2018

by Sweta Killa

Inside the top performing stocks of the top ETF of the first half of 2018.

    Achieve Life Sciences' Shares Rise on Positive Clinical Data

    by Zacks Equity Research

    Achieve Life Sciences' (ACHV) pipeline candidate, cytisine, evaluated for smoking cessation, shows no significant interaction with other medication.

      Kinjel Shah headshot

      Small Drugmakers Edging Out the Bigshots: 7 Stocks to Buy

      by Kinjel Shah

      Smaller drugmakers are having a relatively better year than their larger counterparts. Here are seven stocks to buy.

        Top Ranked Momentum Stocks to Buy for June 19th

        by Zacks Equity Research

        Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 19th:

          Sanghamitra Saha headshot

          Play the Best Sector of Summer With These ETFs & Stocks

          by Sanghamitra Saha

          Health care is apparently one of the best-performing sectors of summer. So, track these ETFs and stocks.

            Why Enanta Pharmaceuticals (ENTA) Could Shock the Market Soon

            by Zacks Equity Research

            Although overlooked by the investors, Enanta Pharmaceuticals (ENTA) looks well-positioned for a solid gain, supported by a favorable Zacks rank and positive estimate revisions.

              Bayer's Generic Competition, Pipeline Setback Issues Remain

              by Zacks Equity Research

              Generic threats/competition for many of its products remain a concern for Bayer (BAYRY).

                Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y

                by Zacks Equity Research

                Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.

                  AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia

                  by Zacks Equity Research

                  AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.

                    Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study

                    by Zacks Equity Research

                    Pfizer (PFE) announces positive top-line results from a phase III study in pediatric epilepsy wherein Lyrica Oral Solution CV meets its primary endpoint.

                      Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion

                      by Zacks Equity Research

                      Zoetis (ZTS) inks a definitive deal to acquire Caifornia-based Abaxis, for $83 per share in cash or a total of $2 billion.

                        Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study

                        by Zacks Equity Research

                        Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.

                          Roche's Actemra Gets FDA Nod for Subcutaneous Formulation

                          by Zacks Equity Research

                          FDA approves the subcutaneous formulation of Roche's (RHHBY) Actemra for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years or older.

                            Sweta Killa headshot

                            Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?

                            by Sweta Killa

                            Style Box ETF report for FYC

                              Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat

                              by Zacks Equity Research

                              Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.

                                Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down

                                by Zacks Equity Research

                                Celldex (CLDX) reports wider-than-expected loss in Q1 but sales beat estimates. It discontinues development of its lead pipeline candidate following its failure in breast cancer study.

                                  Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down

                                  by Zacks Equity Research

                                  Geron (GERN) beats earnings but on lower sales in Q1. Operating expenses were lower year over year.

                                    Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss

                                    by Zacks Equity Research

                                    Intrexon (XON) incurs narrower-than-expected loss but revenues missed mark in the first quarter of 2018.

                                      Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up

                                      by Zacks Equity Research

                                      Endocyte (ECYT) incurs narrower-than-expected loss in the first quarter of 2018. The company finalized a phase III VISION study design for its pipeline candidate 177Lu-PSMA-617 in the quarter.

                                        Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses

                                        by Zacks Equity Research

                                        Catalyst reported in-line loss in Q1. The company resubmitted a new drug application for its lead candidate Firdapse and expects FDA to accept the NDA in Q2.

                                          Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus

                                          by Zacks Equity Research

                                          Ophthotech (OPHT) reports narrower year-over-year loss for the first quarter.

                                            VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters

                                            by Zacks Equity Research

                                            VIVUS (VVUS) reports narrower-than-expected loss for the first quarter. However, Qsymia sales fall from the year-ago period.

                                              Will Agency Growth Aid Booking Holdings (BKNG) Q1 Earnings?

                                              by Zacks Equity Research

                                              Booking Holdings' (BKNG) Q1 earnings are likely to reflect growth in international markets.

                                                ImmunoGen (IMGN) Q1 Loss Wider Than Expected, Revenues Beat

                                                by Zacks Equity Research

                                                ImmunoGen (IMGN) reports wider-than-expected loss in Q1. Lower license and milestone fees resulted in substantial decrease in year-over-revenues.

                                                  FDA Okays Label Expansion of Pacira's Exparel's, Stock Up

                                                  by Zacks Equity Research

                                                  Shares of Pacira (PCRX) jump by about 12.9% after its drug Exparel gets approval by the FDA for an expanded indication.